Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major pneumonia markets are expected to exhibit a CAGR of 5.32% during 2024-2034.
The pneumonia market has been comprehensively analyzed in IMARC's new report titled "Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pneumonia is an infection that causes swelling and fluid or pus buildup in the alveoli (air sacs) of one or both lungs. It may range from moderate to severe and affect people of all ages, but it is most dangerous for older adults, infants, and those with a weakened immune system. The common symptoms of the ailment include coughing with phlegm or pus, fever, chills, difficulty breathing, chest pain, vomiting, nausea, loss of appetite, fatigue, confusion, etc. In severe cases, individuals suffering from this illness may also experience increased heart rate, palpitations, body pain, as well as bluish lips or nails. The diagnosis of pneumonia typically involves a combination of medical history, physical examination, and various diagnostic tests. The healthcare provider will further evaluate the lungs using a stethoscope to check for abnormal sounds, such as crackling or wheezing. A chest X-ray is also utilized among patients that helps to identify the presence of inflammation or fluid in the lungs. Several other investigations, such as sputum culture, a pulse oximetry test, a blood workup, etc., are additionally required to confirm a diagnosis.
The increasing cases of HIV/AIDS and cancer, which can weaken the immune system, making an individual more vulnerable to infections, are primarily driving the pneumonia market. In addition to this, the rising incidences of exposure to hazardous chemicals and smoking, which damage the respiratory system and impair the lung's ability to clear bacteria and other harmful substances, are also creating a positive outlook for the market. Moreover, the widespread adoption of effective antibiotics, including macrolides, penicillin, cephalosporins, etc., to support the body's immune system and reduce symptoms associated with the ailment among patients is further bolstering the market growth. Apart from this, the escalating application of chest physiotherapy techniques, such as percussion, vibration, and postural drainage that help to loosen and mobilize mucus from the lungs, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of nebulized medications on account of their numerous benefits over oral therapies, like improved drug distribution, better absorption, and a quicker onset of action, is expected to drive the pneumonia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the pneumonia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for pneumonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pneumonia market in any manner.
Recent Developments:
In November 2023, Biotest found that Trimodulin reduces mortality in patients with severe community-acquired pneumonia by quick normalization of inflammation. Trimodulin is a novel human plasma protein preparation that is under advanced development for treating pneumonia. It supports and modifies the dysregulated immune system of patients with severe community-acquired pneumonia.
In July 2023, the US FDA granted a qualified infectious disease product (QIDP) designation to Aridis Pharmaceuticals' IgG1 monoclonal antibody AR-301 (tosatoxumab). AR-301 is currently in a Phase III trial to assess its safety and efficacy as an additional therapy for ventilator-associated pneumonia.
In June 2023, Eagle Pharmaceuticals, Inc. announced that the United States FDA has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act and Fast Track Designation, for CAL02, an anti-infective agent being developed to treat severe community-acquired bacterial pneumonia (SCABP) as an add-on regimen to the standard of care.
In June 2023, Clarametyx Biosciences, Inc. reported positive initial safety findings from Phase 1a of its clinical development program for CMTX-101, a novel immune-enabling antibody treatment intended to treat serious bacterial infections. CMTX-101 is designed as an adjunctive therapy to standard?of?care antibiotics for treating moderate community-acquired bacterial pneumonia (CABP) among hospitalized patients.
Key Highlights:
The estimated worldwide incidence of pneumonia varies between 1.5 to 14 cases per 1000 person-years.
Pneumonia prevalence was highest in the pediatric population (6.8%), followed by the geriatric population (3.75%), and most pronounced in non-metro cities (with populations under 1 million).
The annual incidence of pneumonia in the U.S. is 24.8 cases per 10,000 adults.
Among patients with severe pneumonia who necessitate hospitalization, reported mortality rates range from 4% to 37% and rise with age.
Pneumonia is the most common infectious cause of death among children worldwide. The disease causes 14% of all fatalities among children under the age of five, according to the WHO.
Drugs:
Avycaz is a combination of cephalosporin, ceftazidime, and avibactam, a beta-lactamase inhibitor, used to treat hospital-acquired and ventilator-associated bacterial pneumonia in patients aged 18 and older. It is supplied as a sterile powder for injection in single-dose vials containing 2 grams of ceftazidime and 0.5 grams of avibactam.
Tosatoxumab (KBSA301) constitutes a human immunoglobulin G1 monoclonal antibody that neutralizes the alpha-toxin (alpha-hemolysin; Hla) of S. aureus. The drug candidate binds to alpha-toxin's N-terminal epitope in order to block functional toxin pore oligomerisation. Tosatoxumab has the potential to be used as a passive immunotherapy in S. aureus pneumonia, in addition to standard antibiotic therapy.
CAL02 is a novel, first-in-class anti-infective drug that functions as a competitive lure for bacterial virulence variables that cause infection-related complications, sepsis, septic shock, and mortality. CAL02 is made up of patented liposomes developed to capture the virulence factors generated by a wide spectrum of gram-negative and gram-positive bacteria that cause pneumonia. Its activity is complementary to that of antibiotics, and it does not appear to impose any selective pressure that could lead to antibiotic resistance.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pneumonia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pneumonia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pneumonia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pneumonia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pneumonia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pneumonia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pneumonia across the seven major markets?
What is the number of prevalent cases (2018-2034) of pneumonia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pneumonia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with pneumonia across the seven major markets?
What is the size of the pneumonia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pneumonia?
What will be the growth rate of patients across the seven major markets?
Pneumonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pneumonia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pneumonia market?
What are the key regulatory events related to the pneumonia market?
What is the structure of clinical trial landscape by status related to the pneumonia market?
What is the structure of clinical trial landscape by phase related to the pneumonia market?
What is the structure of clinical trial landscape by route of administration related to the pneumonia market?
The pneumonia market has been comprehensively analyzed in IMARC's new report titled "Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pneumonia is an infection that causes swelling and fluid or pus buildup in the alveoli (air sacs) of one or both lungs. It may range from moderate to severe and affect people of all ages, but it is most dangerous for older adults, infants, and those with a weakened immune system. The common symptoms of the ailment include coughing with phlegm or pus, fever, chills, difficulty breathing, chest pain, vomiting, nausea, loss of appetite, fatigue, confusion, etc. In severe cases, individuals suffering from this illness may also experience increased heart rate, palpitations, body pain, as well as bluish lips or nails. The diagnosis of pneumonia typically involves a combination of medical history, physical examination, and various diagnostic tests. The healthcare provider will further evaluate the lungs using a stethoscope to check for abnormal sounds, such as crackling or wheezing. A chest X-ray is also utilized among patients that helps to identify the presence of inflammation or fluid in the lungs. Several other investigations, such as sputum culture, a pulse oximetry test, a blood workup, etc., are additionally required to confirm a diagnosis.
The increasing cases of HIV/AIDS and cancer, which can weaken the immune system, making an individual more vulnerable to infections, are primarily driving the pneumonia market. In addition to this, the rising incidences of exposure to hazardous chemicals and smoking, which damage the respiratory system and impair the lung's ability to clear bacteria and other harmful substances, are also creating a positive outlook for the market. Moreover, the widespread adoption of effective antibiotics, including macrolides, penicillin, cephalosporins, etc., to support the body's immune system and reduce symptoms associated with the ailment among patients is further bolstering the market growth. Apart from this, the escalating application of chest physiotherapy techniques, such as percussion, vibration, and postural drainage that help to loosen and mobilize mucus from the lungs, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of nebulized medications on account of their numerous benefits over oral therapies, like improved drug distribution, better absorption, and a quicker onset of action, is expected to drive the pneumonia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the pneumonia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for pneumonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pneumonia market in any manner.
Recent Developments:
In November 2023, Biotest found that Trimodulin reduces mortality in patients with severe community-acquired pneumonia by quick normalization of inflammation. Trimodulin is a novel human plasma protein preparation that is under advanced development for treating pneumonia. It supports and modifies the dysregulated immune system of patients with severe community-acquired pneumonia.
In July 2023, the US FDA granted a qualified infectious disease product (QIDP) designation to Aridis Pharmaceuticals' IgG1 monoclonal antibody AR-301 (tosatoxumab). AR-301 is currently in a Phase III trial to assess its safety and efficacy as an additional therapy for ventilator-associated pneumonia.
In June 2023, Eagle Pharmaceuticals, Inc. announced that the United States FDA has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act and Fast Track Designation, for CAL02, an anti-infective agent being developed to treat severe community-acquired bacterial pneumonia (SCABP) as an add-on regimen to the standard of care.
In June 2023, Clarametyx Biosciences, Inc. reported positive initial safety findings from Phase 1a of its clinical development program for CMTX-101, a novel immune-enabling antibody treatment intended to treat serious bacterial infections. CMTX-101 is designed as an adjunctive therapy to standard?of?care antibiotics for treating moderate community-acquired bacterial pneumonia (CABP) among hospitalized patients.
Key Highlights:
The estimated worldwide incidence of pneumonia varies between 1.5 to 14 cases per 1000 person-years.
Pneumonia prevalence was highest in the pediatric population (6.8%), followed by the geriatric population (3.75%), and most pronounced in non-metro cities (with populations under 1 million).
The annual incidence of pneumonia in the U.S. is 24.8 cases per 10,000 adults.
Among patients with severe pneumonia who necessitate hospitalization, reported mortality rates range from 4% to 37% and rise with age.
Pneumonia is the most common infectious cause of death among children worldwide. The disease causes 14% of all fatalities among children under the age of five, according to the WHO.
Drugs:
Avycaz is a combination of cephalosporin, ceftazidime, and avibactam, a beta-lactamase inhibitor, used to treat hospital-acquired and ventilator-associated bacterial pneumonia in patients aged 18 and older. It is supplied as a sterile powder for injection in single-dose vials containing 2 grams of ceftazidime and 0.5 grams of avibactam.
Tosatoxumab (KBSA301) constitutes a human immunoglobulin G1 monoclonal antibody that neutralizes the alpha-toxin (alpha-hemolysin; Hla) of S. aureus. The drug candidate binds to alpha-toxin's N-terminal epitope in order to block functional toxin pore oligomerisation. Tosatoxumab has the potential to be used as a passive immunotherapy in S. aureus pneumonia, in addition to standard antibiotic therapy.
CAL02 is a novel, first-in-class anti-infective drug that functions as a competitive lure for bacterial virulence variables that cause infection-related complications, sepsis, septic shock, and mortality. CAL02 is made up of patented liposomes developed to capture the virulence factors generated by a wide spectrum of gram-negative and gram-positive bacteria that cause pneumonia. Its activity is complementary to that of antibiotics, and it does not appear to impose any selective pressure that could lead to antibiotic resistance.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pneumonia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pneumonia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pneumonia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pneumonia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pneumonia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pneumonia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pneumonia across the seven major markets?
What is the number of prevalent cases (2018-2034) of pneumonia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pneumonia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with pneumonia across the seven major markets?
What is the size of the pneumonia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pneumonia?
What will be the growth rate of patients across the seven major markets?
Pneumonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pneumonia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pneumonia market?
What are the key regulatory events related to the pneumonia market?
What is the structure of clinical trial landscape by status related to the pneumonia market?
What is the structure of clinical trial landscape by phase related to the pneumonia market?
What is the structure of clinical trial landscape by route of administration related to the pneumonia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PNEUMONIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PNEUMONIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PNEUMONIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PNEUMONIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PNEUMONIA - UNMET NEEDS
10 PNEUMONIA - KEY ENDPOINTS OF TREATMENT
11 PNEUMONIA - MARKETED PRODUCTS
11.1 List of Pneumonia Marketed Drugs Across the Top 7 Markets
11.1.1 Avycaz (Avibactam/ceftazidime) - Allergan/Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Recarbrio (Cilastatin/imipenem/relebactam) - Merck Sharp and Dohme
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Fetroja (Cefiderocol) - Shionogi
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Nuzyra (Omadacycline) - Paratek Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Xenleta (Lefamulin) - Nabriva Therapeutics
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PNEUMONIA - PIPELINE DRUGS
12.1 List of Pneumonia Pipeline Drugs Across the Top 7 Markets
12.1.1 KBSA301 - Aridis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AR-105 - Aridis Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CAL02 - Eagle Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Trimodulin - Biotest
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 CMTX101 - Clarametyx Biosciences
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PNEUMONIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PNEUMONIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PNEUMONIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pneumonia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pneumonia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pneumonia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pneumonia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pneumonia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pneumonia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pneumonia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pneumonia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pneumonia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pneumonia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pneumonia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pneumonia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pneumonia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pneumonia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pneumonia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pneumonia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pneumonia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pneumonia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pneumonia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pneumonia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pneumonia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pneumonia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pneumonia - Access and Reimbursement Overview
16 PNEUMONIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PNEUMONIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PNEUMONIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PNEUMONIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PNEUMONIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PNEUMONIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PNEUMONIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PNEUMONIA - UNMET NEEDS
10 PNEUMONIA - KEY ENDPOINTS OF TREATMENT
11 PNEUMONIA - MARKETED PRODUCTS
11.1 List of Pneumonia Marketed Drugs Across the Top 7 Markets
11.1.1 Avycaz (Avibactam/ceftazidime) - Allergan/Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Recarbrio (Cilastatin/imipenem/relebactam) - Merck Sharp and Dohme
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Fetroja (Cefiderocol) - Shionogi
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Nuzyra (Omadacycline) - Paratek Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Xenleta (Lefamulin) - Nabriva Therapeutics
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PNEUMONIA - PIPELINE DRUGS
12.1 List of Pneumonia Pipeline Drugs Across the Top 7 Markets
12.1.1 KBSA301 - Aridis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AR-105 - Aridis Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CAL02 - Eagle Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Trimodulin - Biotest
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 CMTX101 - Clarametyx Biosciences
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PNEUMONIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PNEUMONIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PNEUMONIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pneumonia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pneumonia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pneumonia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pneumonia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pneumonia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pneumonia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pneumonia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pneumonia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pneumonia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pneumonia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pneumonia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pneumonia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pneumonia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pneumonia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pneumonia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pneumonia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pneumonia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pneumonia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pneumonia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pneumonia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pneumonia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pneumonia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pneumonia - Access and Reimbursement Overview
16 PNEUMONIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PNEUMONIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PNEUMONIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
